AC
BCYC

AXQ Capital’s Bicycle Therapeutics BCYC Stock Holding History

AXQ Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Buy
+63,134
New +$361K 0.04% 609

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AXQ Capital's BCYC Position: Q1 2026 in Review

AXQ Capital opened a new position in Bicycle Therapeutics (BCYC) in Q1 2026: 63,134 shares worth $293K. The stake represents 0.04% of the portfolio and ranks #609 among its holdings.

98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • AXQ Capital held 63,134 shares of Bicycle Therapeutics worth $293K as of Q1 2026.
  • Bicycle Therapeutics was a new AXQ Capital position in Q1 2026.
  • Bicycle Therapeutics made up 0.04% of AXQ Capital's portfolio in Q1 2026, its #609 holding.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.